Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata

•We evaluated the efficacy of voriconazole (VRC) against 27 Candida glabrata isolates with varying MICs.•We assessed whether VRC in vitro activity is predictive of in vivo efficacy using an immunosuppressed murine model of candidiasis by C. glabrata.•VRC showed efficacy against strains with MICs<0.25μg/mL, variable efficacy when MIC=0.25μg/mL and no efficacy at MIC≥0.5μg/mL.•The epidemiological cut-off value for voriconazole against C. glabrata is 0.25μg/mL; our results showed efficacy at MIC<0.25μg/mL.